NCT05040776View on ClinicalTrials.gov

COVID-19 ThromboprophylaXIs Study of Novel FXIa Inhibitor Frunexian (EP-7041) in ICU Patients

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2023

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2025

Conditions
ThrombopeniaCovid19
Interventions
DRUG

EP-7041 Injection

EP-7041 infusion

Trial Locations (1)

90073

VA Greater Los Angeles Healthcare System, Los Angeles

Sponsors
All Listed Sponsors
lead

eXIthera Pharmaceuticals

INDUSTRY

NCT05040776 - COVID-19 ThromboprophylaXIs Study of Novel FXIa Inhibitor Frunexian (EP-7041) in ICU Patients | Biotech Hunter | Biotech Hunter